In 2005, Sarfaraz et al. showed that patients with more advanced prostate cancer (higher Gleason score, larger tumor size, or metastatic at diagnosis) had CB1R overexpressed and thus associated with worst prognosis [25]. Here, CNR1 is linked to prostate carcinoma.